SCHEMBL10111441

SCHEMBL10111441

CC(C)N1CCC2(CCN(C(C)C)C2)C1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.39
HRH3 Q9Y5N1 3/20 0.35
CYP3A4 P08684 4/20 0.33
ALOX15 P16050 1/20 0.33
CYP1A2 P05177 3/20 0.33
TSHR P16473 3/20 0.33
CYP2C19 P33261 3/20 0.33
CYP2C9 P11712 2/20 0.31
HIF1A Q16665 1/20 0.30
PARP1 P09874 1/20 0.30
CHRNA7 P36544 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10111455 0.92 CYP2D6 (0.38) CYP2D6HRH3
SCHEMBL10111446 0.92 CYP2D6 (0.42) CYP2D6HRH3CHRNA7KDM4EMEN1
SCHEMBL13070658 0.92 CYP2D6 (0.38) CYP2D6HRH3
SCHEMBL10111448 0.92 CYP2D6 (0.42) CYP2D6HRH3CYP3A4ALOX15CYP1A2
SCHEMBL10111450 0.91 CYP2D6 (0.39) CYP2D6HRH3CYP3A4ALOX15CYP1A2
SCHEMBL24536393 0.89 HRH3 (0.34) CYP2D6HRH3
SCHEMBL10094137 0.89 CYP3A4 (0.34) CYP2D6HRH3CYP3A4CYP1A2TSHR
SCHEMBL19300389 0.89 HRH3 (0.34) CYP2D6HRH3
SCHEMBL10255913 0.87 CYP2D6 (0.35) CYP2D6HRH3CYP3A4ALOX15CYP1A2
SCHEMBL17658849 0.87 CYP2D6 (0.35) CYP2D6HRH3CYP3A4ALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. 2024-07-04 US disclosed
EP-4389751-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Kumquat Biosciences Inc. (US) 2024-06-26 EP disclosed
WO-2024126617-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-06-20 WO disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
WO-2024010810-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
WO-2023220137-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-11787800-B2 BRD9 degraders and uses thereof FOGHORN THERAPEUTICS INC. (US) 2023-10-17 US disclosed
US-11787800-B2 BRD9 degraders and uses thereof FOGHORN THERAPEUTICS INC. (US) 2023-10-17 US disclosed
US-20120252810-A1 FATTY ACID NON-FLUSHING NIACIN DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-10-04 US disclosed
US-20120010186-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2012-01-12 US disclosed
US-20120010186-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2012-01-12 US disclosed
US-20110212958-A1 FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110213028-A1 FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110172240-A1 FATTY ACID FUMARATE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110071129-A1 SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE MSD K.K. (JP) 2011-03-24 US disclosed
US-7247634-B2 Rifamycin derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-07-24 US disclosed
US-7238694-B2 Rifamycin imino derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
US-7202246-B2 Spiro-rifamycin derivatives targeting RNA polymerase CUMBRE PHARMACEUTICALS INC. (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071129-A1 SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE MCHR2, MCHR1, ADRB2 CYP2D6 74/4885HRH3 253/4885CYP3A4 251/4885
US-20120252810-A1 FATTY ACID NON-FLUSHING NIACIN DERIVATIVES AND THEIR USES NAMPT, FASN, FFAR2 CYP2D6 603/4885HRH3 393/4885CYP3A4 853/4885
US-20110172240-A1 FATTY ACID FUMARATE DERIVATIVES AND THEIR USES FH, FASN, ELOVL1 CYP2D6 2169/4885HRH3 4506/4885CYP3A4 2336/4885
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 CYP2D6 3897/4885HRH3 2014/4885CYP3A4 2977/4885
US-20110212958-A1 FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES ELOVL5, ELOVL3, ELOVL6 CYP2D6 952/4885HRH3 2211/4885CYP3A4 1071/4885
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN BRDT, BET1, BRD4 CYP2D6 4337/4885HRH3 454/4885CYP3A4 4445/4885
US-20120010186-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, FASN CYP2D6 942/4885HRH3 4687/4885CYP3A4 828/4885
US-20110213028-A1 FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES FABP1, FFAR4, FABP3 CYP2D6 297/4885HRH3 3386/4885CYP3A4 264/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 CYP2D6 3897/4885HRH3 2014/4885CYP3A4 2977/4885
US-11787800-B2 BRD9 degraders and uses thereof BRD9, BRWD1, BRD2 CYP2D6 3138/4885HRH3 1813/4885CYP3A4 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.